|
1
|
Musallam KM, Cappellini MD, Wood JC, Motta
I, Graziadei G, Tamim H and Taher AT: Elevated liver iron
concentration is a marker of increased morbidity in patients with β
thalassemia intermedia. Haematologica. 96:1605–1612. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
La Nasa G, Argiolu F, Giardini C, Pession
A, Fagioli F, Caocci G, Vacca A, De Stefano P, Piras E, Ledda A, et
al: Unrelated bone marrow transplantation for beta-thalassemia
patients: The experience of the Italian Bone Marrow Transplant
Group. Ann N Y Acad Sci. 1054:186–195. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Galanello R and Origa R: Beta-thalassemia.
Orphanet J Rare Dis. 5:112010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yuan J, Bunyaratvej A, Fucharoen S, Fung
C, Shinar E and Schrier SL: The instability of the membrane
skeleton in thalassemic red blood cells. Blood. 86:3945–3950. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Berger K, Ajani UA, Kase CS, Gaziano JM,
Buring JE, Glynn RJ and Hennekens CH: Light-to-moderate alcohol
consumption and the risk of stroke among U.S. male physicians. N
Engl J Med. 341:1557–1564. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rachmilewitz EA and Giardina PJ: How I
treat thalassemia. Blood. 118:3479–3488. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ley TJ: The pharmacology of hemoglobin
switching: Of mice and men. Blood. 77:1146–1152. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lettre G and Bauer DE: Fetal haemoglobin
in sickle-cell disease: From genetic epidemiology to new
therapeutic strategies. Lancet. 387:2554–2564. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Atweh G and Fathallah H: Pharmacologic
induction of fetal hemoglobin production. Hematol Oncol Clin North
Am. 24:1131–1144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Banan M: Hydroxyurea treatment in
β-thalassemia patients: To respond or not to respond? Ann Hematol.
92:289–299. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ronchi A and Ottolenghi S: To respond or
not to respond to hydroxyurea in thalassemia: A matter of stress
adaptation? Haematologica. 98:657–659. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paikari A and Sheehan VA: Fetal
haemoglobin induction in sickle cell disease. Br J Haematol.
180:189–200. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Inati A, Kahale M, Perrine SP, Chui DH,
Taher AT, Koussa S, Abi Nasr T, Abbas HA and Ghalie RG: A phase 2
study of HQK-1001, an oral fetal haemoglobin inducer, in
β-thalassaemia intermedia. Br J Haematol. 164:456–458. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ronzoni L, Sonzogni L, Fossati G, Modena
D, Trombetta E, Porretti L and Cappellini MD: Modulation of gamma
globin genes expression by histone deacetylase inhibitors: An in
vitro study. Br J Haematol. 165:714–721. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Musallam KM, Taher AT, Cappellini MD and
Sankaran VG: Clinical experience with fetal hemoglobin induction
therapy in patients with β-thalassemia. Blood. 121:2199–2212. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bianchi N, Zuccato C, Lampronti I,
Borgatti M and Gambari R: Fetal Hemoglobin Inducers from the
Natural World: A novel approach for identification of drugs for the
treatment of {beta}-thalassemia and sickle-cell Anemia. Evid Based
Complement Alternat Med. 6:141–151. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fibach E, Bianchi N, Borgatti M, Prus E
and Gambari R: Mithramycin induces fetal hemoglobin production in
normal and thalassemic human erythroid precursor cells. Blood.
102:1276–1281. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ng NY and Ko CH: Natural remedies for the
treatment of beta-thalassemia and sickle cell Anemia-current status
and perspectives in fetal hemoglobin reactivation. Int Sch Res
Notices. 2014:1232572014.PubMed/NCBI
|
|
19
|
Theodorou A, Phylactides M, Forti L,
Cramarossa MR, Spyrou P, Gambari R, Thein SL and Kleanthous M: The
investigation of resveratrol and analogs as potential inducers of
fetal hemoglobin. Blood Cells Mol Dis. 58:6–12. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bu HQ, Liu DL, Wei WT, Chen L, Huang H, Li
Y and Cui JH: Oridonin induces apoptosis in SW1990 pancreatic
cancer cells via p53- and caspase-dependent induction of p38 MAPK.
Oncol Rep. 31:975–982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Owona BA and Schluesener HJ: Molecular
insight in the multifunctional effects of oridonin. Drugs R D.
15:233–244. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang S, Zhang Y, Saas P, Wang H, Xu Y,
Chen K, Zhong J, Yuan Y, Wang Y and Sun Y: Oridonin's therapeutic
effect: Suppressing Th1/Th17 simultaneously in a mouse model of
Crohn's disease. J Gastroenterol Hepatol. 30:504–512. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang X, Chen LX, Ouyang L, Cheng Y and
Liu B: Plant natural compounds: Targeting pathways of autophagy as
anti-cancer therapeutic agents. Cell Prolif. 45:466–476. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao G, Zhang T, Ma X, Jiang K, Wu H, Qiu
C, Guo M and Deng G: Oridonin attenuates the release of
pro-inflammatory cytokines in lipopolysaccharide-induced RAW264.7
cells and acute lung injury. Oncotarget. 8:68153–68164.
2017.PubMed/NCBI
|
|
25
|
Wu QX, Yuan SX, Ren CM, Yu Y, Sun WJ, He
BC and Wu K: Oridonin upregulates PTEN through activating p38 MAPK
and inhibits proliferation in human colon cancer cells. Oncol Rep.
35:3341–3348. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang S, Yu L, Yang H, Li C, Hui Z, Xu Y
and Zhu X: Oridonin attenuates synaptic loss and cognitive deficits
in an Aβ1-42-induced mouse model of Alzheimer's disease. PLoS One.
11:e01513972016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aerbajinai W, Zhu J, Gao Z, Chin K and
Rodgers GP: Thalidomide induces gamma-globin gene expression
through increased reactive oxygen species-mediated p38 MAPK
signaling and histone H4 acetylation in adult erythropoiesis.
Blood. 110:2864–2871. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pace BS, Liu L, Li B and Makala LH: Cell
signaling pathways involved in drug-mediated fetal hemoglobin
induction: Strategies to treat sickle cell disease. Exp Biol Med
(Maywood). 240:1050–1064. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wei GH, Zhao GW, Song W, Hao DL, Lv X, Liu
DP and Liang CC: Mechanisms of human gamma-globin transcriptional
induction by apicidin involves p38 signaling to chromatin. Biochem
Biophys Res Commun. 363:889–894. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ramakrishnan V and Pace BS: Regulation of
gamma-globin gene expression involves signaling through the p38
MAPK/CREB1 pathway. Blood Cells Mol Dis. 47:12–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sangerman J, Lee MS, Yao X, Oteng E, Hsiao
CH, Li W, Zein S, Ofori-Acquah SF and Pace BS: Mechanism for fetal
hemoglobin induction by histone deacetylase inhibitors involves
gamma-globin activation by CREB1 and ATF-2. Blood. 108:3590–3599.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Marx V: Epigenetics: Reading the second
genomic code. Nature. 491:143–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Traycoff CM, Abboud MR, Laver J, Brandt
JE, Hoffman R, Law P, Ishizawa L and Srour EF: Evaluation of the in
vitro behavior of phenotypically defined populations of umbilical
cord blood hematopoietic progenitor cells. Exp Hematol. 22:215–222.
1994.PubMed/NCBI
|
|
34
|
Fibach E and Prus E: Differentiation of
human erythroid cells in culture. Curr Protoc Immunol. Chapter 22:
Unit 22F.7. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cuenda A, Rouse J, Doza YN, Meier R, Cohen
P, Gallagher TF, Young PR and Lee JC: SB 203580 is a specific
inhibitor of a MAP kinase homologue which is stimulated by cellular
stresses and interleukin-1. FEBS Lett. 364:229–233. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Thein SL: The emerging role of fetal
hemoglobin induction in non-transfusion-dependent thalassemia.
Blood Rev. 26 (Suppl 1):S35–S39. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pourfarzad F, von Lindern M, Azarkeivan A,
Hou J, Kia SK, Esteghamat F, van Ijcken W, Philipsen S, Najmabadi H
and Grosveld F: Hydroxyurea responsiveness in β-thalassemic
patients is determined by the stress response adaptation of
erythroid progenitors and their differentiation propensity.
Haematologica. 98:696–704. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rigano P, Pecoraro A, Calzolari R, Troia
A, Acuto S, Renda D, Pantalone GR, Maggio A and Di Marzo R:
Desensitization to hydroxycarbamide following long-term treatment
of thalassaemia intermedia as observed in vivo and in primary
erythroid cultures from treated patients. Br J Haematol.
151:509–515. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fathallah H, Taher A, Bazarbachi A and
Atweh GF: Differences in response to fetal hemoglobin induction
therapy in beta-thalassemia and sickle cell disease. Blood Cells
Mol Dis. 43:58–62. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ma Z: Study on immune regulation of
Rabdosia rubescens and its safety assessment (unpublished PhD
thesis). Central South University, Public Health. 2010.(In
Chinese).
|
|
42
|
Zang K, Du L, Liu X, Ma J and Ren Y:
Therapeutic effect of oridonin tablet on acetic acid-induced
ulcerative colitis in mice. Chin J Modern Applied Pharmacy.
29:781–785. 2012.(In Chinese).
|
|
43
|
Ma Z, Hu C and Zhang Y: Therapeutic effect
of Rabdosia rubescens aqueous extract on chronic pharyngitis and
its safety. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 36:170–173.
2011.(In Chinese). PubMed/NCBI
|
|
44
|
Deng Xu-xia and Lyu Xiang: Efficency
compirson of Herba Rabidosiae Rubescentis dripping pills and Herba
Rabdosiae Rubescentis buccal tablets in the treatment of recurrent
oral ulcer. Henan Traditional Chin Med. 37(4)2017.(In Chinese).
|
|
45
|
Mabaera R, West RJ, Conine SJ, Macari ER,
Boyd CD, Engman CA and Lowrey CH: A cell stress signaling model of
fetal hemoglobin induction: What doesn't kill red blood cells may
make them stronger. Exp Hematol. 36:1057–1072. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pace BS, Qian XH, Sangerman J,
Ofori-Acquah SF, Baliga BS, Han J and Critz SD: p38 MAP kinase
activation mediates gamma-globin gene induction in erythroid
progenitors. Exp Hematol. 31:1089–1096. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cokic VP, Andric SA, Stojilkovic SS,
Noguchi CT and Schechter AN: Hydroxyurea nitrosylates and activates
soluble guanylyl cyclase in human erythroid cells. Blood.
111:1117–1123. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hsiao CH, Li W, Lou TF, Baliga BS and Pace
BS: Fetal hemoglobin induction by histone deacetylase inhibitors
involves generation of reactive oxygen species. Exp Hematol.
34:264–273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Oh HN, Seo JH, Lee MH, Yoon G, Cho SS, Liu
K, Choi H, Oh KB, Cho YS, Kim H, et al: Oridonin induces apoptosis
in oral squamous cell carcinoma probably through the generation of
reactive oxygen species and the p38/JNK MAPK pathway. Int J Oncol.
Mar 16–2018.doi: 10.3892/ijo.2018.4319 (Epub ahead of print).
View Article : Google Scholar :
|
|
50
|
Huang J, Wu LS, Tashiro S, Onodera S and
Ikejima T: Reactive oxygen species mediate oridonin-induced HepG2
apoptosis through p53, MAPK, and mitochondrial signaling pathways.
J Pharmacol Sci. 107:370–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
